The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...

New UK clinical trials regulations have been signed into law, with a 12-month rollout starting 11 April. The reforms mark the ...

Birmingham researchers have received £230k from Cancer Research Horizons to develop a prototype test for monitoring people ...

A systematic literature review identified 362 records from 67 studies across 10 countries. Results showed romosozumab significantly improved bone mineral density at 12 months in lumbar spine, total ...

SkyCell has partnered with Microsoft to launch SkyMind, an artificial intelligence (AI)-powered solution designed to enhance ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

The NHS has started delivering its spring COVID-19 vaccine booster to vulnerable individuals across England, with over half a ...